HEARTS Package Evaluation Trial in Bangladesh
Evaluation of the WHO HEARTS Hypertension Control Package in the Primary Care Clinics of Bangladesh: A Quasi-experimental Trial
1 other identifier
interventional
3,935
1 country
14
Brief Summary
Hypertension became the leading risk factor of death globally as well as in Bangladesh. Uncontrolled hypertension is the key challenge for the success of a hypertension control programs. According to the last national STEPS Survey in Bangladesh, hypertension control rate is only 11%. World Health Organization promoted the HEARTS technical package for the hypertension control programs to improve the control scenario. National Heart Foundation of Bangladesh is implementing a hypertension control program in selected Upazilas (sub-districts) of Bangladesh in collaboration with Non-Communicable Disease Control (NCDC) Program of Directorate General of Health Services (DGHS) and Resolve to Save Lives, USA. Proposed quasi experimental study will be conducted in collaboration with NCDC of DGHS, Resolve to Save Lives, USA and Johns Hopkins University, Baltimore with an objective of to evaluate the impact of HEARTS package on the rate of hypertension control in primary health care centers in Bangladesh. In this study equal number of hypertensive adult patients will be recruited in Upazila Health Complexes of control and intervention groups with a hypothesis of, implementation of HEARTS technical package in primary health care centers can reduce the blood pressure significantly. After obtaining informed written consent, respondents' basic demographic information, history of antihypertensive medication intake and related comorbidities will be taken. Blood pressure measurements data will be recorded also. All of these data will be collected via a secured mobile application, Simple App. Collected data will be preserved in a secured cloud based database. After six months of enrolment, and end-line data will be collected at the community setup, preferably at the home of respondents, following standard techniques of BP measurement by experienced Field Research Assistants. During whole of the study procedure, every ethical right of the participants will be preserved with an utmost priority. De-identified data will be shared with the partner organizations for further scientific analysis. This study will generate robust evidence for use of HEARTS technical packages in low-and middle-income countries, like Bangladesh, especially at low-level health facilities and provide guidance for designing and implementation of other hypertension control programs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable hypertension
Started Oct 2021
Shorter than P25 for not_applicable hypertension
14 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 28, 2021
CompletedFirst Posted
Study publicly available on registry
August 5, 2021
CompletedStudy Start
First participant enrolled
October 9, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 12, 2022
CompletedJuly 14, 2023
July 1, 2023
3 months
July 28, 2021
July 13, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Difference in differences of systolic blood pressure (SBP)
defined as between- group difference in BP change at six months (BP change at six months calculated for each group as end-line minus baseline mean systolic BP)
Six months
Secondary Outcomes (6)
Difference in differences of diastolic blood pressure (DBP)
Six months
Difference in differences of rate of hypertension control.
Six months
Rate of loss to follow-up.
Six months
Difference in differences of rate of hypertension control (Measured in the clinic)
Six months
Rate of loss to follow up
Six months
- +1 more secondary outcomes
Study Arms (2)
Control Arm
NO INTERVENTIONParticipants of this arm will not receive the total WHO HEARTS package as an intervention. These participants will be screened in the designated area for universal BP screening via A\&D arm-in device. Their diagnosis will be confirmed by measuring their BP by a Medical Officer via an Omron desktop oscillometer. The Medical Officers and UHC nurses of the control sites will be trained up on BP measurement using standard techniques, patient registration, data collection, etc.
Intervention Arm
EXPERIMENTALParticipants of this arm will receive all the components of WHO HEARTS technical package components as an intervention.
Interventions
Components of WHO HEARTS technical package are 1. Universal BP screening via A\&D arm-in BP device. 2. Training of Medical Officers and Nurses on BP measurement using standard techniques. 3. Training of the nurses on screening, registration data collection via the Simple mobile smart-phone digital clinical hypertension information application. 4. Use of a drug and dose specific hypertension treatment protocol. 5. Standardized inventory and procurement practice to ensure a reliable supply of protocol medications. 6. Training and support for team-based model of hypertension care delivery. 7. Access to the Simple data dashboard for program monitoring. 8. Standardized procedure for patient follow-up. 9. Community-based prescription refilling.
Eligibility Criteria
You may qualify if:
- Aged 18 and above
- Have a diagnosis of hypertension (inclusive of known prior diagnosis or a new diagnosis), with a baseline systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg
- Eligible for the HEARTS technical package, i.e., are not pregnant, not being treated for an acute illness or medical emergency, and do not have a terminal illness.
You may not qualify if:
- Previously diagnosed hypertensive patients with a controlled BP at the time of enrollment (systolic BP \<140 mmHg and diastolic BP \< 90 mmHg). Either BP is controlled using diet and lifestyle measures or BP is controlled on antihypertensive medications,
- Cognitive impairment that would prevent comprehension of and responding to questions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (14)
Madarganj Upazila Health Complex
Jāmālpur, Dhaka Division, 1207, Bangladesh
Baniachang Upazila Health Complex
Habiganj, Bangladesh
Madhabpur Upazila Health Complex
Habiganj, Bangladesh
Bakhshiganj Upazila Health Complex
Jamālpur, Bangladesh
Dewanganj Upazila Health Complex
Jamālpur, Bangladesh
Islampur Upazila Health Complex
Jamālpur, Bangladesh
Melandaha Upazila Health Complex
Jamālpur, Bangladesh
Sarishabari Upazila Health Complex
Jamālpur, Bangladesh
Karimganj Upazila Health Complex
Kishoreganj, Bangladesh
Katiadi Upazila Health Complex
Kishoreganj, Bangladesh
Tarail Upazila Health Complex
Kishoreganj, Bangladesh
Biswamvarpur Upazila Health Complex
Sunāmganj, Bangladesh
Doarabajar Upazila Health Complex
Sunāmganj, Bangladesh
Gowainghat Upazila Health Complex
Sylhet, Bangladesh
Related Publications (6)
Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016 Aug 9;134(6):441-50. doi: 10.1161/CIRCULATIONAHA.115.018912.
PMID: 27502908BACKGROUNDKaur P, Kunwar A, Sharma M, Mitra J, Das C, Swasticharan L, Chakma T, Dipak Bangar S, Venkatasamy V, Dharamsoth R, Purohit S, Tayade S, Singh GB, Bitragunta S, Durgad K, Das B, Dar S, Bharadwaj R, Joshi C, Bharadwaj V, Khedkar S, Chenji S, Reddy SK, Sreedhar C, Parasuraman G, Kasiviswanathan S, Viswanathan V, Uike P, Gaigaware P, Yadav S, Dhaliwal RS, Ramakrishnan S, Tullu FT, Bhargava B. India Hypertension Control Initiative-Hypertension treatment and blood pressure control in a cohort in 24 sentinel site clinics. J Clin Hypertens (Greenwich). 2021 Apr;23(4):720-729. doi: 10.1111/jch.14141. Epub 2020 Dec 23.
PMID: 33369074BACKGROUNDBloom DE, Cafiero E, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, Feigl AB, Gaziano T, Hamandi A, Mowafi M, O'Farrell D. The global economic burden of noncommunicable diseases. Program on the Global Demography of Aging; 2012 Jan.
BACKGROUNDWorld Health Organization. National STEPS survey for non-communicable diseases risk factors in Bangladesh 2018.
BACKGROUNDWorld Health Organization. HEARTS Technical package for cardiovascular disease management in primary health care. Geneva: WHO; 2016.
BACKGROUNDAbrar A, Hu X, Akhtar J, Jubayer S, Noor Nabi Sayem M, Sultana S, Al Mamun MA, Bhuiyan MR, Malik F, Amin MR, Alim A, Gupta R, Zhao D, Farrell M, Banigbe B, Matsushita K, Burka D, Appel L, Moran AE, Choudhury SR. Evaluation of the World Health Organization-HEARTS hypertension control package in Bangladesh: a quasi-experimental trial. Heart. 2024 Aug 14;110(17):1090-1098. doi: 10.1136/heartjnl-2024-324253.
PMID: 39019496DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sohel R Choudhury, PhD
National Heart Foundation Hospital and Research Institute
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 28, 2021
First Posted
August 5, 2021
Study Start
October 9, 2021
Primary Completion
December 31, 2021
Study Completion
August 12, 2022
Last Updated
July 14, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- After completion of data collection, deidentified IPD will be shared with the collaborators and those will be available for them till completion of the report writeup.
- Access Criteria
- IPD will be shared will the collaborator researchers who will participate in the data analysis and report writing.
Deidentified IPD will be shared with the other researchers.